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Targeting translation initiation is an emerging anti-
neoplastic strategy that capitalizes on de-regulated
upstream MAPK and PI3K-mTOR signaling path-
ways in cancers. A key regulator of translation that
controls ribosome recruitment flux is eukaryotic
initiation factor (eIF) 4F, a hetero-trimeric complex
composed of the cap binding protein eIF4E, the scaf-
folding protein eIF4G, and the RNA helicase eIF4A.
Small molecule inhibitors targeting eIF4F display
promising anti-neoplastic activity in preclinical set-
tings. Among these are some rocaglate family
members that are well tolerated in vivo, deplete
eIF4F of its eIF4A helicase subunit, have shown ac-
tivity as single agents in several xenograft models,
and can reverse acquired resistance to MAPK and
PI3K-mTOR targeted therapies. Herein, we highlight
the power of using genetic complementation ap-
proaches and CRISPR/Cas9-mediated editing for
drug-target validation ex vivo and in vivo, linking
the anti-tumor properties of rocaglates to eIF4A
inhibition.
INTRODUCTION
Protein synthesis is a tightly controlled process that is deregu-
lated in many human cancers and is required to sustain several
cancer hallmarks (Bhat et al., 2015). In part, this is attributed to
hyper-activation of the MAPK and PI3K-mTOR pathways, both
of which impact on the activity of eukaryotic initiation factor
(eIF) 4F. As well, resistance to targeted therapies aimed at inhib-
iting the PI3K-mTOR and MAPK signaling pathways in various
cancers has been linked to elevated eIF4F activity (Bhat et al.,
2015). Therefore, there is significant interest in developing2340 Cell Reports 15, 2340–2347, June 14, 2016 ª 2016 The Author(
This is an open access article under the CC BY-NC-ND license (http://eIF4F inhibitors as anti-neoplastic compounds (Bhat et al.,
2015).
The eIF4F heterotrimeric complex binds to m7GpppN mRNA
cap structures through its eIF4E subunit, remodels proximal sec-
ondary structure via its eIF4A RNA helicase subunit, and recruits
40S ribosomes (with associated initiation factors) through its
eIF4G subunit. The mammalian genome encodes two highly
related (>90% identity) eIF4A isoforms, eIF4A1 and eIF4A2.
These two isoforms were initially thought to be functionally
redundant, but there is evidence suggesting they may also
possess distinct biological properties (Galicia-Va´zquez et al.,
2012).
Strategies aimed at inhibiting eIF4F include blocking
eIF4E:eIF4G and eIF4E-cap interaction, interfering with eIF4A1/2
activity, and suppressing eIF4E expression with antisense oligo-
nucleotides (ASOs) (Bhat et al., 2015). The development of eIF4E
ASOs has provided proof-of-concept validation for targeting
eIF4F in xenograft models, as well as generating safety data
profiling from phase I clinical trials (Graff et al., 2007; Hong
et al., 2011). Transient inhibition of eIF4E (and hence eIF4F) is
tolerated at the organismal level (Lin et al., 2012), despite its
essential nature (Truitt et al., 2015). The most potent small mole-
cule inhibitors of the eIF4F complex derive from a family of com-
pounds referred to as rocaglates, which are characterized by
a common cyclopenta[b]benzofuran skeleton. Extensive struc-
ture-activity relationship into the biological activity of these
compounds has been obtained (Pan et al., 2014), with a few com-
pounds capable of potently inhibiting translation (Bordeleau
et al., 2008; Rodrigo et al., 2012).
Rocaglates decrease eIF4A1/2 levels present in the eIF4F
complex (Bordeleau et al., 2008), exhibit anti-tumor activity in a
number of pre-clinical models (Bordeleau et al., 2008; Cencic
et al., 2009; Wolfe et al., 2014), and are thought to exert their ef-
fects by preferentially inhibiting the translation of key oncogenic
mRNAs (e.g., MYC) (Cencic et al., 2009; Rubio et al., 2014; Wolfe
et al., 2014). Chemogenomic profiling in yeast have identified the
eIF4A orthologs, TIF1 and TIF2, as targets of rocaglates (Sadlishs)
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Generation and Characterization
of a Rocaglate-Resistant eIF4A1 Allele
(A) Schematic illustrating conserved motifs of
the DEAD-box helicase family. Sequences of the
conserved motifs are denoted with motifs involved
in RNA binding highlighted in bold red. The struc-
ture of eIF4A indicates it to be dumbbell in shape
with two domains (I and II) linked via a flexible linker
sequence. The inset shows a ribbon diagram of
eIF4A1 (PDB 2ZU6) aligned to eIF4A3 (not shown;
PDB 2HYI). The residues targeted for mutagenesis
are highlighted and the single-stranded RNA
substrate (positioned relative to the eIF4A3 crystal
structure) is shown in orange.
(B) Coomassie stain of purified recombinant
eIF4A1 proteins.
(C) Assessment of ATP hydrolysis by recombinant
proteins via thin layer chromatography.
(D) Kinetics of ATP hydrolysis by eIF4A1 and
eIF4A1(F163L). ATPase assays were performed
with 1 mg protein and varying ATP concentrations.
Graph represents the Michaelis-Menten fit from
two independent experiments.
(E) RNA binding activity of eIF4A1 and eIF4A1
(F163L) using [32P]-labeled RNA generated from
pSP/CAT (see Supplemental Experimental Pro-
cedures). Assays were performed in the presence
of 0.5% DMSO or 1 mM silvestrol and the retained
eIF4A:RNA complexes are set relative to DMSO
controls. n = 3 biological replicates performed in
triplicate ±SEM; *p < 0.001.
(F) Quantitation of eIF4A1 and eIF4A1(F163L)
helicase activity performed with 0.5 mg recombi-
nant eIF4A1 and an 11-nt radiolabeled RNAduplex
in the presence of DMSO or 50 mM silvestrol. n = 3
biological replicates ±SEM; *p < 0.05.
(G) DSF analysis of eIF4A1 or eIF4A1(F163L) in the
presence of DMSO or ()-SDS-1-021.et al., 2013). However, prohibitins (PHB) 1 and 2 have also been
proposed as potential rocaglate targets inmammals (Polier et al.,
2012). PHB1/2 are involved in a variety of processes, including
activation of MAPK signaling (Rajalingam et al., 2005). Given
the possibility of alternative targets (PHB1/2 or others), it is crit-
ical to validate the rocaglate-eIF4A1/2 drug target relationship
in vivo since poor drug-target characterization is a frequent
cause of drug development failures (Smurnyy et al., 2014).
Here, we validate the rocaglate-eIF4A1 drug target relation-
ship by identifying a drug-resistant and functional mammalianCell ReIF4A1 allele that is capable of rescuing
rocaglate anti-neoplastic activity upon
introduction into cells either by genetic
complementation or genome editing.
RESULTS
eIF4A1 F163L Is Unresponsive to
Rocaglates In Vitro
We previously identified mutations in the
yeast eIF4A orthologs, TIF1 and TIF2,
that conferred resistance to rocaglates,which mapped to the TIF-RNA interface (P147Q, F151L, and
Q183E) (Sadlish et al., 2013). We sought to determine whether
analogous mutations in the mammalian setting (P159Q and
F163L) could inform on the eIF4A:rocaglate relationship. P159Q
and F163L map within, or adjacent of, the conserved TPGR
Ib motif, which along with the PTRELA motif, is implicated in
RNA binding (Figure 1A). Following purification of recombinant
proteins (Figure 1B), we performed ATPase assays and noted
that eIF4A1(F163L), but not eIF4A1(P159Q), retained robust
ATPase activity (Figure 1C). The kinetics of ATP hydrolysis byeports 15, 2340–2347, June 14, 2016 2341
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Figure 2. Ectopic Expression of eIF4A1
(F163L) Confers Resistance to Rocaglates
in Mammalian Cells
(A) Schematic diagram of RCV designed to
simultaneously express an shRNA-resistant His6-
eIF4A1 allele while suppressing endogenous
eIF4A1.
(B) Representative western blot of NIH/3T3 cells
transduced with RCVs. The dashed line separates
the two sets of western blots.
(C) Viability assay of RCV-transduced NIH/3T3
cells. Cells were exposed to the indicated con-
centrations of silvestrol and relative viability was
assessed 6 days later by sulforhodamine B (SRB).
n = 2 biological replicates performed in dupli-
cates ±SEM.
(D) Competition assay of transduced NIH/3T3
cells. Transduced cells (GFP+) were mixed with
parental cells (GFP–) and cultured in the presence
of 20 nM silvestrol. The percentage of GFP+ cells
was determined on the indicated days. n = 2 bio-
logical replicates performed in triplicate ±SEM.
(E) Cells expressing eIF4A1(F163L) are resistant to
translation inhibition by silvestrol. Transduced
cells were incubated with the indicated concen-
trations of silvestrol for 1 hr and labeled with [35S]-
methionine/cysteine during the last 15 min. n = 4
biological replicates ±SEM.
(F) Polysome profiles of transduced NIH/3T3 cells
following exposure to 200 nM silvestrol for 30 min.
P/M represents the polysome/monosome ratio.
n = 3 biological replicates ±SEM.
See also Figure S1.eIF4A1(F163L) were similar to wild-type (WT) eIF4A and to pub-
lished values (Figure 1D) (Lorsch and Herschlag, 1998). Since
rocaglates increase the RNA binding of eIF4A and lead to its
depletion from the eIF4F complex (Bordeleau et al., 2008; Ro-
drigo et al., 2012), wemonitored binding of eIF4A1 to 32P-labeled
RNA in vitro.Whereas silvestrol stimulatedWTeIF4A1:RNAbind-
ing, eIF4A1(F163L):RNA complex formation was unaffected (Fig-
ure 1E). As well, eIF4A1(F163L) helicase activity was comparable
to WT eIF4A1 but remained unaffected by silvestrol (Figure 1F).
Rocaglate resistance of eIF4A1(F163L) was also demon-
strated using differential scanning fluorimetry (DSF) (Figure 1G).
This approach monitors temperature-dependent protein unfold-
ing with an increase in fluorescence arising from dye binding to
newly exposed hydrophobic domains. Protein/ligand interac-
tions are expected to promote protein stability, leading to a shift
(increase) in denaturation temperature (Niesen et al., 2007).
As this approach consumes large quantities of compounds, we
used the related synthetic rocaglate ()-SDS-1-021 instead
of the scarcer natural product silvestrol (Figure S1A). In our
hands, ()-SDS-1-021 is more active than silvestrol with respect
to stimulating eIF4A RNA binding activity (Chu et al., 2016), in-
hibiting translation (Chu et al., 2016), and affecting cell viability
(Figure S1B). Only WT eIF4A1 showed a transition midpoint tem-2342 Cell Reports 15, 2340–2347, June 14, 2016perature shift of +2–3C (Figure 1G),
which is consistent with the ability of ro-
caglates to interact with eIF4A1, but notas robustly (if at all) with eIF4A1(F163L). Taken together, these
experiments indicate that eIF4A1(F163L) ATPase activity and
RNA binding are resistant to rocaglates in vitro while displaying
Vmax and Km values for ATP hydrolysis that are similar to WT
eIF4A1.
Introduction of eIF4A1(F163L) Confers Cellular
Resistance to Silvestrol
To determine whether eIF4A1(F163L) could complement for loss
of WT eIF4A1 in cellulo, we engineered a retroviral complemen-
tation vector (RCV) that affords simultaneous small hairpin RNA
(shRNA)-mediated suppression of endogenous eIF4A1 while
co-expressing exogenous His-tagged eIF4A1 (Figure 2A). As
previously reported, knockdown of eIF4A1 led to increased
expression of eIF4A2 (Figure 2B) (Galicia-Va´zquez et al., 2012).
Ectopic expression of WT eIF4A1 or eIF4A1(F163L), but not
the inactive eIF4A1(P159Q) mutant, rescued this response (Fig-
ure 2B). Cells expressing eIF4A1(F163L) showed resistance to
silvestrol as assessed by monitoring cell viability (Figure 2C),
growth competition assays (Figure 2D), 35S-methionine meta-
bolic labeling (Figure 2E), and polysome profiling (Figure 2F).
The resistance phenotype observed upon ectopic expression
of the eIF4A1(F163L) allele was not pleiotropic since these cells
were still sensitive to the structurally unrelated eIF4A inhibitor,
hippuristanol (Figures S1A and S1C). Taken together, these re-
sults demonstrate that the eIF4A1(F163L) allele can functionally
compensate for suppression of eIF4A1 and is sufficient to confer
cellular resistance to silvestrol.
Cas9-Mediated Editing of the Eif4a1 Locus Rescues
Cells from the Inhibitory Effects of Rocaglates
To strengthen these results, we utilized CRISPR/Cas9 gene edit-
ing to introduce the F163L mutation into the endogenous Eif4a1
locus. To this end, two sgRNAs were designed to target Eif4a1
exon 5 and co-transfected with a single-stranded oligonucleo-
tide (ssODN) donor template (Figure 3A). In addition to harboring
the desired F163L change, two silent mutations were present in
the ssODN that altered the protospacer adjacent motifs (PAMs)
to prevent re-cleavage (Figure 3A, indicated in red). Control
cells received Cas9 and sgRNAs targeting the neutral Rosa26
locus (Rosa26em1JP). Two cell populations, eIF4A1em1JP and
eIF4A1em2JP, derived from sgRNA2 and sgRNA1, respectively,
were characterized by sequencing exon 5 PCR products (Fig-
ure 3B). The results indicate that the eIF4A1em1JP population
contains Eif4a1 alleles that harbor CTT or CTC codons encoding
for leucine at position 163, whereas the eIF4A1em2JP population
also has Eif4a1 alleles with deletions within exon 5 (Figures 3B
and S2A). No silvestrol-resistant colonies arose from Rosa26
targeted cells, and we did not detect mutant Eif4a1 alleles in
Rosa26em1JP cells. The growth of eIF4A1em1JP cells showed
increased resistance (10-fold) to silvestrol and ()-SDS-1-
021 (Figure S2B). To ensure that the observed resistance
was not due to off-target alterations by CRISPR/Cas9, we
suppressed the mutated Eif4a1 alleles in eIF4A1em1JP and
eIF4A1em2JP using the RCV system (Figures 3C and 3D). Resen-
sitization was monitored using 35S-methionine/cysteine protein
labeling. As expected eIF4A1em1JP showed increased resistance
(10- to 20-fold) to silvestrol compared to control Rosa26em1JP
cells (Figure 3C). Importantly, suppressing endogenous
eIF4A1(F163L) using sh4A1.372 and co-expressing WT eIF4A1
resensitized eIF4A1em1JP cells to silvestrol (Figure 3C). Similar
results were also obtained with eIF4A1em2JP cells (Figure 3C).
To assess whether eIF4A1(F163L) showed altered rocaglate
binding in cellulo, we implemented a cellular thermal shift assay
(CETSA) by measuring the thermal stability of WT eIF4A1 or
eIF4A1(F163L) fromRosa26em1JP and eIF4A1em1JP cells, respec-
tively, that had been exposed to vehicle or ()-SDS-1-021 (Fig-
ure 3E). In this assay, thermal stability is assessed by heating
cells over a range of temperatures, followed by separation of
insoluble (i.e., denatured/aggregated) from soluble proteins (Ja-
fari et al., 2014). Levels of the protein of interest remaining in the
soluble fractions are then determined by immunoblotting. Similar
to DSF, CETSA is based on the principle that thermal stability of a
protein is increased upon binding to a ligand (Jafari et al., 2014).
For Rosa26em1JP cells, WT eIF4A1 displayed a 2C increase in
thermal stability when cells were exposed to ()-SDS-1-021
(Figure 3E). For eIF4A1em1JP cells, we observed no differences
in the denaturation profile of eIF4A1(F163L), suggesting reduced
target engagement for eIF4A1(F163L) (Figure 3E).
We next investigated the relationship between eIF4A1 status
and the in vivo anti-neoplastic activity of rocaglates. To thisend, Rosa26em1JP and eIF4A1em1JP cells were transduced with
a retrovirus expressing Myr-Akt and single clones from these
populations were isolated (referred to as Rosa26em1JP(Myr-
Akt), eIF4A1em1JP(Myr-Akt#1), and eIF4A1em1JP(Myr-Akt#2)).
The relative distribution of the different Eif4a1 alleles in
eIF4A1em1JP(Myr-Akt#1) was assessed by cloning and se-
quencing exon 5 PCR products and revealed the presence of
four different Eif4a1(F163L) alleles in approximately equimolar
ratios, with no intragenic deletions (Figures S3A and S3B). These
results are consistent with NIH/3T3 cells being tetraploid for
chromosome 11 (the location of murine Eif4a1) (Leibiger et al.,
2013). Direct sequencing of the exon 5 PCR products indepen-
dently demonstrated that a mixture of CTC and CTT alleles
were present (Figure S3B). Colony formation assays demon-
strated that eIF4A1em1JP(Myr-Akt#1) cells were resistant to roca-
glates ex vivo (Figure 4A). In vivo, eIF4A1em1JP(Myr-Akt#1) cells
formed tumors faster than Rosa26em1JP(Myr-Akt) cells (Fig-
ure 4B), despite displaying similar doubling rates ex vivo (Fig-
ure S3C). Nevertheless, an 8-day treatment coursewith silvestrol
significantly curtailed tumor outgrowth in mice transplanted
with Rosa26em1JP(Myr-Akt) cells while having no effect on
eIF4A1em1JP(Myr-Akt#1) tumors (Figure 4B). Independently
generated tumors from the second cell line, eIF4A1em1JP(Myr-
Akt#2), formed tumors slower than eIF4A1em1JP(Myr-Akt#1) in
mice but nonetheless remained unresponsive to silvestrol (Fig-
ure 4B). The failure to respond to silvestrol in vivo was associated
with an 3-fold reduction in apoptosis (Figure 4C). Previous
studies have identified several rocaglate-responsive mRNAs,
of which c-myc is a representative anti-cancer target (Robert
et al., 2014; Wolfe et al., 2014). Polysome analysis revealed
that c-myc mRNA distribution shifts from heavy polysome frac-
tions to light polysome fractions when Rosa26em1JP(Myr-Akt)
cells were exposed to silvestrol but remains unaffected in
eIF4A1em1JP(Myr-Akt#1) cells (Figures 4D and 4E). Translation
of Atp5o, a prototypical mRNA harboring a translation initiator
of short 50 UTR (TISU) element, which confers eIF4A indepen-
dence (Elfakess et al., 2011), was unaffected when either cell
line was exposed to silvestrol (Figure 4E). Immunoblotting and
immunoprecipitation of metabolically labeled proteins were
consistent with the ability of silvestrol to inhibit MYC protein
production in Rosa26em1JP(Myr-Akt), but not eIF4A1em1JP(Myr-
Akt#1), cells (Figure S4). These results indicate that the anti-
neoplastic activity of silvestrol is a consequence of eIF4A1
suppression, which subsequently is associated with diminished
expression of Myc, a quintessential oncogene.
DISCUSSION
Using genetic complementation and CRISPR/Cas9-mediated
gene editing, we validate eIF4A1 as the primary molecular target
of rocaglates in mammalian cells responsible for the inhibition of
translation observed with this class of compounds. These results
significantly strengthen the drug-target link between rocaglates
and eIF4A1 in vivo and were critical to undertake since roca-
glates have also been reported to bind to prohibitins (PHB) 1
and 2 and block their interaction with cRaf (Polier et al., 2012).
Our results indicate that this is not the mechanism by which ro-
caglates inhibit translation (Chu et al., 2016) and in our handsCell Reports 15, 2340–2347, June 14, 2016 2343
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Figure 3. Cas9-Mediated Editing of Eif4a1
(A) Strategy for introducing the Eif4a1(F163L) mutant allele. The sequence of two sgRNAs targeting exon 5 and the partial sequence of the ssODN donor are
shown. The PAMs are shaded, and the nucleotide changes in the ssODN donor that abolishes their presence are indicated in red. The targeted TTT (F) codon is
indicated by a dashed orange box, and engineered CTC (L) change in the ssODN donor is indicated in green.
(B) Sequence analysis of the PCR products from eIF4A1em1JP and eIF4A1em2JP cells indicating loss of the wild-type Eif4a1 allele and composition of mutant
alleles.
(C) Relative translation rates in Rosa26em1JP, eIF4A1em1JP, eIF4A1em2JP cells transduced with the indicated retroviruses.
(D) Western blot assessing His6-eIF4A1 and total eIF4A1 in the cell lines used in (C).
(E) CETSA of Rosa26em1JP and eIF4A1em1JP cells. Cells were incubated with 1 mM ()-SDS-1-021 or DMSO for 1 hr at 37C and heated at the indicated
temperatures for 3 min. Soluble lysates were prepared and used for western blotting. n = 4 biological replicates ±SEM.
See also Figure S2.
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Figure 4. Cas9-Mediated Editing of the Eif4a1 Locus Confirms the Drug-Target Hypothesis
(A) Colony formation assay of Myr-Akt-transformed Rosa26em1JP or eIF4A1em1JP cells in the presence of silvestrol.
(B) Response of Myr-Akt-transformed Rosa26em1JP or eIF4A1em1JP xenografts in vivo to silvestrol. On the indicated days, mice were treated with silvestrol
(0.2 mg/kg) following tumor appearance. n = 6–7 mice/cohort ±SEM.
(C) Bar graph of the percentage of apoptotic nuclei from tumor sections. Three hours before harvesting of tumors, mice were treated with vehicle or 0.2 mg/kg
silvestrol. n = 2 biological replicates (with 7,000 nuclei analyzed per tumor) ±SD; *p < 0.05; ns, not significant.
(D) Polysome profiles of Myr-Akt-transformed Rosa26em1JP or eIF4A1em1JP cells exposed to 10 nM silvestrol for 1 hr.
(E) Distribution of mRNAs in polysome fractions shown in (D).
See also Figures S3 and S4.cannot be responsible for the ex vivo or in vivo activity of roca-
glates. However, rocaglates may have other unsuspected bio-
logical targets. Although both eIF4A1 and eIF4A2 can cycle
through the eIF4F complex in vitro (Yoder-Hill et al., 1993), there
is emerging evidence suggesting that their activities are not
interchangeable (Galicia-Va´zquez et al., 2012). Whether eIF4A2
plays a significant role in response to rocaglate-mediated inhi-
bition and could be responsible for the partial sensitivity of
eIF4A1em1JP to high rocaglate concentration (Figure S2B) re-
mains to be elucidated. Nevertheless, these results consolidate
the position of eIF4A1 as an anti-cancer target.
We were surprised to find several alleles of Eif4a1(F136L) in
our silvestrol-resistant population, both at the codon encoding
leucine and at the PAM motifs (Figures 3B, S3A, and S3B).
This may be a consequence of strand-switching during homol-
ogy directed repair (HDR) occurring before incorporation of the
second mutation present on the ODN. This has previously
been documented when simultaneously introducing two muta-
tions at a given locus, with as much as a 17% drop in efficiency
occurring with mutations positioned 8–10 bp apart (Elliott et al.,1998; Yang et al., 2013). These results highlight the impor-
tance of thorough characterization of cell lines generated by
CRISPR/Cas9.
In silico analysis of the yeast TIF1/2 proteins predicted a roca-
glate-binding pocket at the TIF1-RNA interface (Sadlish et al.,
2013). Our results from DSF and CETSA assays are consistent
with rocaglates directly interacting with eIF4A in vitro and in cel-
lulo. Although structural studies of eIF4A1-rocaglate interaction
are necessary to unequivocally identify the rocaglate binding
site and understand how the F163L mutation affects rocaglate
binding, our results suggest that eIF4A1(F136L) is likely resistant
to rocaglates due to reduced compound engagement (Figures
1G and 3E).
Precise genome editing of change-of-function alleles coupled
with drug selection has been shown to be a powerful approach to
generate tailored cell lines and validate drug:target interactions
(Smurnyy et al., 2014). Our results extend this paradigm to
gain-of-function alleles coupled with activity screening to vali-
date drug-target relationships in vivo. Although our previous
work had identified several TIF1 alleles as capable of conferringCell Reports 15, 2340–2347, June 14, 2016 2345
rocaglate-resistance in yeast (Sadlish et al., 2013), we found that
not all corresponding Eif4a1 alleles encoded for functional pro-
teins in the mammalian setting. This highlights the importance
of undertaking detailed biochemical studies coupled with an
approach, such as the RCV system (Figure 2), to demonstrate
complementation before undertaking the more labor- and
time-intensive task of engineering the alleles into the cellular
genome. Our genetic complementation and genome editing
approaches, in combination with in cellulo and in vivo data
converge to position eIF4A1 as a critical anti-neoplastic target.
EXPERIMENTAL PROCEDURES
Cell Lines and Retrovirus Generation
All cell lines were cultured in DMEMsupplementedwith 10% fetal bovine serum
(FBS), 100 U/ml penicillin/streptomycin, and 2mML-glutamine at 37C and 5%
CO2. For retroviral transductions, 25 mg of plasmid was transfected into
ecotropic Phoenix cells using calciumphosphate in thepresence of 25 mMchlo-
roquine, and themediawaschanged the followingday.Starting48hr after trans-
fection, viral supernatantwasfilteredandadded toNIH/3T3cells in thepresence
of 4 mg/ml polybrene. Cells were spinoculated at 1,0003 g for 1 hr at 30C. In-
fections were performed every 8 hr, for a total of six infections. Cas9-modified
cell lines are named as suggested (http://www.informatics.jax.org/mgihome/
nomen/gene.shtml#endim); for example, eIF4A1em1JP indicates the first endo-
nuclease-induced mutation (em1) of the Eif4a1 gene produced in J.P.’s lab).
Xenograft Models
Fourmillion cells were injectedwithMatrigel subcutaneously into 4- to 6-week-
old female Balb/c-nu/numice. Tumor growth wasmonitored every second day
using calipers. Treatments began when tumors had reached 25–50 mm3 with
silvestrol (0.2 mg/kg) delivered by intraperitoneal (IP) injection daily for 8
consecutive days. Tumor growth was monitored for the remainder of the
experiment, and no further drug treatments were performed. For tumor anal-
ysis, mice were treated with compound or vehicle 3 hr prior to harvesting of
the tumors. Tumors were collected into 10% formalin, embedded in paraffin,
and sectioned. TUNEL staining was performed using the DeadEnd Fluoro-
metric TUNELSystem (Promega) according to themanufacturer’s instructions.
The percentage of cells undergoing apoptosis was determined by counting the
number of TUNELpositive nuclei on Fiji (ImageJ, NIH) and dividing it by the total
number of nuclei in the field. All animal studies were approved by the McGill
University Faculty of Medicine Animal Care Committee.
Additional details regardingmethodology are presented in the Supplemental
Experimental Procedures.
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and four figures and can be found with this article online at http://dx.doi.org/
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